Inhaled Insulin Returns To The U.S. Market With Afrezza Launch
This article was originally published in The Pink Sheet Daily
Sanofi announced the launch of the inhaled insulin in the U.S. Feb. 3, priced at a wholesale acquisition cost that is higher than rival injectable mealtime insulins.
You may also be interested in...
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Production of insulin powder inhaler cartridges at Connecticut facility will triple to 400 million a year by launch, which firm expects in 2015.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.